Skip to content

Greencare Capital - Directorate Changes


Announcement provided by

MaxRets Ventures Plc · MAX

28/04/2022 07:00

Greencare Capital - Directorate Changes
RNS Number : 6744J
Greencare Capital PLC
28 April 2022
 

 

 

28 April 2022

 

Greencare Capital PLC

("Greencare" or the "Company")

Directorate Changes

 

Greencare (AQSE: GRE), the investment company focused on investing in medicinal cannabis, CBD and related wellness areas, announces the following Board changes with immediate effect.

 

Mr Dominic White joins the Board as Non-Executive Chairman and Mr Martin Walton has been appointed an independent Non-executive Director. Richard Tonthat  is stepping down as Chief Executive Officer in order to pursue other business interests. Mr Guy Winterflood, who has been a Non-executive Director since the Company's flotation, is also stepping down from the Board in order to devote more time to his Chairmanship of Hempflax BV of The Netherlands, one of Europe's largest growers of Hemp for industrial use.  

 

Dominic White has over 25 years' experience in the investment sector and has managed more than £3 billion of assets in the UK and Europe across multiple sectors, in public companies, funds, joint-ventures and regulated activities. He has held Board Level executive and non-executive positions in numerous public companies and international investment institutions such as Henderson Global Investors. Mr White is a member of the Institute of Chartered Financial Analysts.

 

Mr White is Executive Chairman of AQSE quoted Eight Capital Partners plc and is on the Board of a number of other private companies.

 

Martin Walton has many years' experience at Board level of companies within the life sciences, biotech and medtech sectors/industries and within investment and commercial banking. He is currently a Non-executive Director of AIM listed Reneuron Group plc, a UK-based leader in Stem Cell and Exosomes Technologies and is Chairman and CEO of Bradshaw Consulting Limited, a strategic advisory group assisting companies and shareholders in creating, generating and realising value from investments in life sciences and tech sectors. He was previously at Excalibur Group Fund Management, was a co-founder of Arix Bioscience plc and Arthurian Life Sciences Limited and has held senior positions at Standard Bank and Toronto-Dominion Bank.     

 

On joining the Board as Non-Executive Chairman, Mr White commented:

"On behalf of the Board, I would like to thank both Richard and Guy for their commitment and service to the Company over the past two years, and wish them well in their future endeavours. I also welcome Martin to the Board where his combined life sciences and corporate finance and investment banking experience will be of great value as the Company moves forward.

 

"I am pleased to have the opportunity to join Greencare at this time.   The CBD and cannabis sector continues to develop, and, as it matures, we expect there to be opportunities, consolidation and rationalisation. Greencare will continue to actively pursue acquisition and investment opportunities of varying size in the cannabis and wellbeing space as well as taking a broader view of opportunities within our stated investing strategy

 

 

 

Enquiries:

 

Greencare Capital plc

Dominic White 

C/O Wakbrook PR Limited

+44 (0)20 7933 8780

 

 

Cairn Financial Advisers LLP

AQSE Corporate Adviser

Jo Turner / James Lewis

 

 

+44 (0)20 7213 0880

 

 

 

 

Walbrook PR Limited

Paul Vann/Nick Rome

 

+44 (0)20 7933 8780

+44 (0)7768 807631

greencarecapital@walbrookpr.com

 

 

The following information is disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

 

Dominic Andrew White (aged 50) holds or has held the following directorships or partnerships in the past five years:

 

Current Directorships or Partnerships

Previous Directorships or Partnerships

Dharma Dragon Ltd

12250088 Limited (previously Supply@Me Capital Limited)

Eight Capital Partners PLC

Drumz PLC

E-Ledger Capital Solutions Ltd

eMed Pharma Group Limited

IWEP Ltd

Maximum Return System Ltd

K&C (Coleherne) Limited

Ovio Wellness Limited

K&C (Newbury) Limited

Supply@Me Capital PLC

K&C (Osprey) Limited

Windustries Ltd

KCR (Kite) Limited

Zamaz PLC

KCR (Southampton) Limited

 

KCR Residential Reit PLC

 

Maximum Return System Ltd

 

Maximum Return Systems Group LLP

 

White Amba Ltd

 

 

Mr White holds 8,000,000 Ordinary shares in the Company through a holding entity, representing 54.1% of its issued share capital. Eight Capital Partners plc, a company of which Mr White is a director and significant shareholder, holds 2,560,000 ordinary shares in the Company representing 17.3% of its issued share capital.

 

Mr White was a director of Ovio Wellness Limited, a health drinks company, which was dissolved in February 2019 following the company being placed into creditors voluntary liquidation in August 2017.

 

Mr Martin Charles Walton (aged 58 ) holds or has held the following directorships or partnerships in the past five years:

 

Current Directorships or Partnerships

Previous Directorships or Partnerships

ReNeuron Group plc

Anontec Limited

Bradshaw Consulting Ltd

Arix Capital Management Limited

Excalibur Medicines Ltd

Arthurian Life Sciences Gp Limited

Igraine plc

Arthurian Life Sciences Spv Gp Limited

Interrad Medical Inc

Excalibur Fund Managers Limited

 

Iatros Capital Limited

 

Iota Sciences Limited

 

PZT Limited

 

Simbec-Orion Group Limited

 

 

Mr Walton does not hold any shares in the Company.

 

There is no further information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Rulebook.

 

Notes:

Greencare Capital plc is an investment company quoted on the Aquis Stock Exchange Growth Market ("AQSE"). The Company was incorporated on 1 October 2019 and its shares were admitted to trading on 30 December 2019.

 

The Company's investment strategy is to focus on investments in cannabis sectors within countries predominantly in Europe whose jurisdictions have well-developed and reputable laws and regulations for its production, research and distribution; together with the CBD and hemp sectors.

 

The Company will invest directly or indirectly in public or private companies, in supply and distribution chains, or other business associated with the cannabis sector. Investments may take the form of debt or equity and it is expected that such investments will ordinarily seek capital growth in the medium term in preference to income.

 

The Company will not invest in the recreational cannabis sector, or in entities or activities supported by it, nor any other related activities which would be deemed illegal under UK legislation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXKZGZDKRFGZZG ]]>

View more ...

MAX announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal